IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-509-3751202
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
OptionableNot Optionable
IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions
What is IsoRay's stock symbol?
IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
How were IsoRay's earnings last quarter?
IsoRay, Inc. (NYSEAMERICAN:ISR) released its quarterly earnings results on Tuesday, February, 12th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The healthcare company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million. View IsoRay's Earnings History.
When is IsoRay's next earnings date?
What price target have analysts set for ISR?
3 analysts have issued 12-month price objectives for IsoRay's stock. Their predictions range from $1.00 to $2.00. On average, they expect IsoRay's share price to reach $1.3333 in the next twelve months. This suggests a possible upside of 281.0% from the stock's current price. View Analyst Price Targets for IsoRay.
What is the consensus analysts' recommendation for IsoRay?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IsoRay.
What are Wall Street analysts saying about IsoRay stock?
Here are some recent quotes from research analysts about IsoRay stock:
- 1. According to Zacks Investment Research, "IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. " (2/13/2019)
- 2. Maxim Group analysts commented, "IsoRay reported the September quarter (FYE: June) with Cs-131 revenue of $1.56M, down 2.5% sequentially, and flat with the Dec and Mar quarters. The company ended the period with $9.2M in cash, including net proceeds of $8.25M from a July equity financing. Our fundamental view of Cs-131 is as a superior isotope for radio-therapy remains intact though IsoRay continues to struggle to drive revenue growth. It’s still early stage for Blu-Build and the question is can GammaTile be the answer? At this point it’s too early to tell and we see only incremental revenue growth. As such, we opt to step down to a Hold rating, from Buy, remove our price target." (11/9/2018)
- 3. HC Wainwright analysts commented, "Our therapeutic models are patient-based, reflecting our assumptions for the market size, and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model." (9/26/2018)
Has IsoRay been receiving favorable news coverage?
Media coverage about ISR stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IsoRay earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news coverage about the healthcare company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Are investors shorting IsoRay?
IsoRay saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,065,703 shares, a decline of 2.9% from the January 15th total of 1,097,591 shares. Based on an average trading volume of 349,208 shares, the short-interest ratio is presently 3.1 days. Currently, 1.6% of the shares of the stock are sold short. View IsoRay's Current Options Chain.
Who are some of IsoRay's key competitors?
Some companies that are related to IsoRay include InfuSystem (INFU), Daxor (DXR), TSO3 (TOS), Retractable Technologies (RVP), Milestone Scientific (MLSS), Relevium Technologies (RLV), Impression Healthcare (IHL), Vigil Health Solutions (VGL), Advanced Medical Solutions (AMS), Akers Biosciences (AKR), ANSELL LTD/S (ANSLY), CONVATEC GRP PL/ADR (CNVVY), Essilor International Cmgn Gnl D Optq (EI), Gerresheimer (GXI) and Iris BioTechnologies (IRSB).
Who are IsoRay's key executives?
IsoRay's management team includes the folowing people:
- Ms. Lori A. Holmes-Woods, CEO & Director (Age 57)
- Mr. William Cavanagh III, COO & Chief Scientific Officer (Age 53)
- Mr. Michael L. Krachon, VP of Sales & Marketing (Age 48)
- Mr. Jonathan R. Hunt, Chief Financial Officer (Age 52)
- Mr. Mark J. Austin CPA, Controller & Principal Accounting Officer (Age 32)
Who are IsoRay's major shareholders?
IsoRay's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Highland Private Wealth Management (0.19%). Company insiders that own IsoRay stock include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, Thomas C Lavoy and William Cavanagh. View Institutional Ownership Trends for IsoRay.
Which institutional investors are buying IsoRay stock?
ISR stock was acquired by a variety of institutional investors in the last quarter, including Highland Private Wealth Management. Company insiders that have bought IsoRay stock in the last two years include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, Thomas C Lavoy and William Cavanagh. View Insider Buying and Selling for IsoRay.
How do I buy shares of IsoRay?
Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IsoRay's stock price today?
One share of ISR stock can currently be purchased for approximately $0.35.
How big of a company is IsoRay?
IsoRay has a market capitalization of $23.57 million. IsoRay employs 38 workers across the globe.
What is IsoRay's official website?
How can I contact IsoRay?
IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.
MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
